Alimera Sciences PE Ratio 2009-2021 | ALIM

Current and historical p/e ratio for Alimera Sciences (ALIM) from 2009 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Alimera Sciences PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Alimera Sciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 4.40 44.00
2021-06-30 9.10 $0.10 91.00
2021-03-31 9.62 $-1.44 0.00
2020-12-31 4.22 $-1.05 0.00
2020-09-30 4.86 $-0.79 0.00
2020-06-30 6.30 $-1.27 0.00
2020-03-31 4.00 $-1.81 0.00
2019-12-31 7.58 $-2.17 0.00
2019-09-30 8.49 $-2.25 0.00
2019-06-30 13.35 $4.20 3.18
2019-03-31 15.90 $4.35 3.66
2018-12-31 10.77 $3.30 3.27
2018-09-30 14.70 $1.80 8.17
2018-06-30 14.67 $-5.25 0.00
2018-03-31 15.45 $-4.95 0.00
2017-12-31 19.95 $-4.80 0.00
2017-09-30 20.25 $-4.65 0.00
2017-06-30 20.85 $-5.85 0.00
2017-03-31 21.00 $-7.50 0.00
2016-12-31 16.20 $-9.75 0.00
2016-09-30 22.35 $-11.99 0.00
2016-06-30 18.45 $-10.05 0.00
2016-03-31 26.25 $-10.64 0.00
2015-12-31 36.30 $-10.20 0.00
2015-09-30 33.15 $-10.05 0.00
2015-06-30 69.15 $-12.14 0.00
2015-03-31 75.15 $-6.90 0.00
2014-12-31 83.10 $-12.29 0.00
2014-09-30 81.30 $-15.89 0.00
2014-06-30 89.70 $-13.94 0.00
2014-03-31 118.35 $-26.39 0.00
2013-12-31 70.50 $-24.29 0.00
2013-09-30 56.40 $-19.79 0.00
2013-06-30 73.20 $-21.74 0.00
2013-03-31 46.05 $-13.94 0.00
2012-12-31 23.55 $-9.45 0.00
2012-09-30 38.70 $-9.75 0.00
2012-06-30 44.85 $-10.34 0.00
2012-03-31 51.00 $-10.64 0.00
2011-12-31 18.75 $-10.79 0.00
2011-09-30 120.00 $-10.94 0.00
2011-06-30 122.25 $-10.79 0.00
2011-03-31 117.00 $-11.24 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.030B $0.051B
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00